Regeneron Pharmaceuticals (REGN) EBIT Margin (2009 - 2026)
Regeneron Pharmaceuticals' quarterly EBIT Margin came in at 17.83% in Q1 2026, down 170.0% year-on-year from 25.47% in Q1 2025, and down 21.28% quarter-over-quarter from 22.65% in Q4 2025.
Regeneron Pharmaceuticals has reported EBIT Margin for 18 years, with the latest figure at 17.83% in Q1 2026.
- For the quarter ending Q1 2026, EBIT Margin fell 170.0% year-over-year to 17.83%; the trailing twelve-month figure through Mar 2026 stood at 24.32% (down 287.0% YoY), and the FY2025 full-year result was 24.95%, down 315.0% from the prior year.
- EBIT Margin for Q1 2026 stood at 17.83%, down from 22.65% in the prior quarter.
- The five-year high for EBIT Margin was 2517.0% in Q1 2022, with the low at 17.83% in Q1 2026.
- Average EBIT Margin over 5 years is 240.97%, with a median of 29.94% recorded in 2023.
- Year-over-year, EBIT Margin soared 247300 bps in 2022 and sank 248706 bps in 2023.
- Tracing REGN's EBIT Margin over 5 years: stood at 1146.8% in 2022, then tumbled by 98 bps to 28.33% in 2023, then dropped by 8 bps to 26.13% in 2024, then slipped by 13 bps to 22.65% in 2025, then slipped by 21 bps to 17.83% in 2026.
- The last three EBIT Margin figures came in at 17.83% (Q1 2026), 22.65% (Q4 2025), and 27.35% (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | -6.43% |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 38.10% |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 17.83% |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 23.02% |
| 10 | Revolution Medicines | 31.20 Bn | 31.20 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 17.83% |
| Dec 31, 2025 | 22.65% |
| Sep 30, 2025 | 27.35% |
| Jun 30, 2025 | 29.37% |
| Mar 31, 2025 | 19.54% |
| Dec 31, 2024 | 26.13% |
| Sep 30, 2024 | 31.70% |
| Jun 30, 2024 | 30.15% |
| Mar 31, 2024 | 23.89% |
| Dec 31, 2023 | 28.33% |
| Sep 30, 2023 | 33.04% |
| Jun 30, 2023 | 32.19% |
| Mar 31, 2023 | 29.94% |
| Dec 31, 2022 | 1,146.80% |
| Sep 30, 2022 | 41.68% |
| Jun 30, 2022 | 38.85% |
| Mar 31, 2022 | 2,517.00% |
| Dec 31, 2021 | 53.31% |
| Sep 30, 2021 | 53.50% |
| Jun 30, 2021 | 65.14% |
| Mar 31, 2021 | 44.00% |
| Dec 31, 2020 | 48.17% |
| Sep 30, 2020 | 45.91% |
| Jun 30, 2020 | 33.63% |
| Mar 31, 2020 | 38.29% |
| Dec 31, 2019 | 36.26% |
| Sep 30, 2019 | 42.35% |
| Jun 30, 2019 | 20.00% |
| Mar 31, 2019 | 34.97% |
| Dec 31, 2018 | 37.25% |
| Sep 30, 2018 | 37.69% |
| Jun 30, 2018 | 38.69% |
| Mar 31, 2018 | 37.53% |
| Dec 31, 2017 | 34.05% |
| Sep 30, 2017 | 37.31% |
| Jun 30, 2017 | 37.43% |
| Mar 31, 2017 | 32.64% |
| Dec 31, 2016 | 28.28% |
| Sep 30, 2016 | 29.73% |
| Jun 30, 2016 | 24.05% |
| Mar 31, 2016 | 27.42% |
| Dec 31, 2015 | 21.04% |
| Sep 30, 2015 | 34.50% |
| Jun 30, 2015 | 34.53% |
| Mar 31, 2015 | 32.61% |
| Dec 31, 2014 | 30.83% |
| Sep 30, 2014 | 25.97% |
| Jun 30, 2014 | 34.26% |
| Mar 31, 2014 | 30.61% |
| Dec 31, 2013 | 31.96% |
| Sep 30, 2013 | 39.66% |
| Jun 30, 2013 | 34.55% |
| Mar 31, 2013 | 34.81% |
| Dec 31, 2012 | 35.13% |
| Sep 30, 2012 | 47.32% |
| Jun 30, 2012 | 28.74% |
| Mar 31, 2012 | 9.58% |
| Dec 31, 2011 | -36.92% |
| Sep 30, 2011 | -56.85% |
| Jun 30, 2011 | -55.95% |
| Mar 31, 2011 | -36.52% |
| Dec 31, 2010 | 97.98% |
| Sep 30, 2010 | -650.20% |
| Jun 30, 2010 | -20.47% |
| Mar 31, 2010 | -1,531.12% |
| Dec 31, 2009 | -300.02% |
| Sep 30, 2009 | -1.10% |
| Jun 30, 2009 | -361.47% |